https://www.selleckchem.com/pr....oducts/compound-3i.h
n with no child protection service contact. These findings suggest the need for a more comprehensive service response for children with protection concerns. After US Food and Drug Administration (FDA) approval of a new drug, sponsors can submit additional clinical data to obtain supplemental approval for use for new indications. To characterize pivotal trials supporting recent supplemental new indication approvals of drugs and biologics by the FDA and to compare them with pivotal trials that supported these therapeutics' original in
Like
Comment
Share
